Q1 Earnings Estimate for Cresco Labs Issued By Roth Capital

Cresco Labs Inc. (OTCMKTS:CRLBF - Free Report) - Equities research analysts at Roth Capital issued their Q1 2025 EPS estimates for Cresco Labs in a note issued to investors on Thursday, March 13th. Roth Capital analyst W. Kirk anticipates that the company will post earnings per share of ($0.03) for the quarter. The consensus estimate for Cresco Labs' current full-year earnings is ($0.20) per share. Roth Capital also issued estimates for Cresco Labs' Q2 2025 earnings at ($0.02) EPS, Q3 2025 earnings at ($0.02) EPS, Q4 2025 earnings at ($0.01) EPS, FY2025 earnings at ($0.08) EPS and FY2026 earnings at ($0.04) EPS.

A number of other brokerages have also issued reports on CRLBF. Cormark raised shares of Cresco Labs from a "hold" rating to a "moderate buy" rating in a research report on Monday. Atb Cap Markets downgraded shares of Cresco Labs from a "strong-buy" rating to a "hold" rating in a research note on Monday, December 9th. Two analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $3.00.

Cresco Labs Stock Performance

CRLBF stock traded up $0.01 on Monday, reaching $0.72. 2,218,801 shares of the company were exchanged, compared to its average volume of 621,663. Cresco Labs has a 12 month low of $0.70 and a 12 month high of $2.60. The stock's fifty day moving average price is $0.87 and its 200 day moving average price is $1.18. The firm has a market capitalization of $349.02 million, a PE ratio of -3.58 and a beta of 1.79. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.97 and a quick ratio of 1.39.

Remove Ads

Cresco Labs (OTCMKTS:CRLBF - Get Free Report) last released its quarterly earnings results on Friday, March 14th. The company reported ($0.01) EPS for the quarter, meeting analysts' consensus estimates of ($0.01). Cresco Labs had a negative net margin of 9.15% and a negative return on equity of 16.52%. The company had revenue of $176.00 million for the quarter, compared to analyst estimates of $172.10 million.

About Cresco Labs

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.